-
Je něco špatně v tomto záznamu ?
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
G. Simonneau, RN. Channick, M. Delcroix, N. Galiè, HA. Ghofrani, P. Jansa, FO. Le Brun, S. Mehta, L. Perchenet, T. Pulido, BK. Sastry, O. Sitbon, R. Souza, A. Torbicki, LJ. Rubin,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 1994 do Před 18 měsíci
Open Access Digital Library
od 1988-01-01
- MeSH
- antagonisté endotelinového receptoru terapeutické užití MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- familiární plicní arteriální hypertenze farmakoterapie mortalita MeSH
- hospitalizace MeSH
- incidence MeSH
- Kaplanův-Meierův odhad MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- plicní hypertenze farmakoterapie mortalita MeSH
- prevalence MeSH
- progrese nemoci MeSH
- proporcionální rizikové modely MeSH
- pyrimidiny terapeutické užití MeSH
- senioři MeSH
- sulfonamidy terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts.Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (≤6 months; n=110) or prevalent (>6 months; n=157). The risk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression.The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and prevalent cohorts (p=0.587). Macitentan 10 mg significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation versus placebo in incident and prevalent cohorts.Incident patients had a higher risk for PAH progression compared with prevalent patients but not a higher risk of death. Macitentan delayed disease progression in both incident and prevalent PAH patients.
Actelion Pharmaceuticals Ltd Allschwil Switzerland
Cardiopulmonary Department Ignacio Chávez National Heart Institute Mexico City Mexico
Department of Cardiology CARE Hospitals Hyderabad India
Department of Pneumology Gasthuisberg University Hospital Leuven Belgium
Pulmonary and Critical Care Massachusetts General Hospital Boston MA USA
Pulmonary Department Heart Institute University of São Paulo Medical School São Paulo Brazil
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028058
- 003
- CZ-PrNML
- 005
- 20161027113222.0
- 007
- ta
- 008
- 161005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1183/13993003.00364-2015 $2 doi
- 024 7_
- $a 10.1183/13993003.00364-2015 $2 doi
- 035 __
- $a (PubMed)26493786
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Simonneau, Gérald $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France gerald.simonneau@bct.aphp.fr.
- 245 10
- $a Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN / $c G. Simonneau, RN. Channick, M. Delcroix, N. Galiè, HA. Ghofrani, P. Jansa, FO. Le Brun, S. Mehta, L. Perchenet, T. Pulido, BK. Sastry, O. Sitbon, R. Souza, A. Torbicki, LJ. Rubin,
- 520 9_
- $a In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts.Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (≤6 months; n=110) or prevalent (>6 months; n=157). The risk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression.The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and prevalent cohorts (p=0.587). Macitentan 10 mg significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation versus placebo in incident and prevalent cohorts.Incident patients had a higher risk for PAH progression compared with prevalent patients but not a higher risk of death. Macitentan delayed disease progression in both incident and prevalent PAH patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a antagonisté endotelinového receptoru $x terapeutické užití $7 D065128
- 650 _2
- $a familiární plicní arteriální hypertenze $x farmakoterapie $x mortalita $7 D065627
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hospitalizace $7 D006760
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plicní hypertenze $x farmakoterapie $x mortalita $7 D006976
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a pyrimidiny $x terapeutické užití $7 D011743
- 650 _2
- $a sulfonamidy $x terapeutické užití $7 D013449
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Channick, Richard N $u Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA.
- 700 1_
- $a Delcroix, Marion $u Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium.
- 700 1_
- $a Galiè, Nazzareno $u Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.
- 700 1_
- $a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center, Giessen, Germany Member of the German Center of Lung Research (DZL), Giessen, Germany Department of Medicine, Imperial College London, London, UK.
- 700 1_
- $a Jansa, Pavel $u Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech Republic.
- 700 1_
- $a Le Brun, Franck-Olivier $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
- 700 1_
- $a Mehta, Sanjay $u Division of Respirology, Department of Medicine, London Health Sciences Centre - Victoria Hospital, Western University, London, ON, Canada.
- 700 1_
- $a Perchenet, Loic $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
- 700 1_
- $a Pulido, Tomás $u Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, Mexico.
- 700 1_
- $a Sastry, B K S $u Department of Cardiology, CARE Hospitals, Hyderabad, India.
- 700 1_
- $a Sitbon, Olivier $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.
- 700 1_
- $a Souza, Rogério $u Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
- 700 1_
- $a Torbicki, Adam $u Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, Otwock, Poland.
- 700 1_
- $a Rubin, Lewis J $u Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, San Diego, CA, USA.
- 773 0_
- $w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 46, č. 6 (2015), s. 1711-20
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26493786 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161027113638 $b ABA008
- 999 __
- $a ok $b bmc $g 1166372 $s 952688
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 46 $c 6 $d 1711-20 $e 20151022 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
- LZP __
- $a Pubmed-20161005
